Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette Sells 10,230 Shares

Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette sold 10,230 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $10.99, for a total transaction of $112,427.70. Following the completion of the transaction, the general counsel now owns 70,544 shares of the company’s stock, valued at approximately $775,278.56. This represents a 12.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Mike Ouimette also recently made the following trade(s):

• On Friday, January 17th, Mike Ouimette sold 13,270 shares of Pliant Therapeutics stock. The shares were sold at an average price of $11.20, for a total transaction of $148,624.00.

Pliant Therapeutics Stock Up 2.0 %

PLRX opened at $11.14 on Friday. The firm’s 50-day simple moving average is $13.18 and its 200-day simple moving average is $13.06. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. Pliant Therapeutics, Inc. has a twelve month low of $10.22 and a twelve month high of $18.92. The firm has a market cap of $677.87 million, a price-to-earnings ratio of -3.34 and a beta of 1.05.

Pliant Therapeutics (NASDAQ:PLRX) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.95) EPS for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.04. Equities research analysts anticipate that Pliant Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of Pliant Therapeutics in a report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pliant Therapeutics presently has a consensus rating of “Buy” and an average target price of $40.50.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PLRX. R Squared Ltd bought a new position in shares of Pliant Therapeutics in the 4th quarter valued at about $33,000. Atria Investments Inc bought a new position in shares of Pliant Therapeutics in the 3rd quarter valued at about $112,000. Deerfield Management Company L.P. Series C bought a new position in shares of Pliant Therapeutics in the 2nd quarter valued at about $126,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Pliant Therapeutics by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock valued at $131,000 after purchasing an additional 4,607 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Pliant Therapeutics in the 3rd quarter valued at about $145,000. Institutional investors own 97.30% of the company’s stock.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.